GSK/Exelixis: The End of an Era
This article was originally published in The Pink Sheet Daily
Executive Summary
Six-year alliance allowed Exelixis to build a pipeline; after gaining $260 million in funding, GSK walks away with rights to only one compound.
You may also be interested in...
Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO
Shortly after the market closed on June 30, Biogen Idec and Exelixis confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos taking the helm of the Big Biotech July 15
Biogen Makes Counterintuitive Move To Tap Exelixis's Scangos As CEO
Shortly after the market closed on June 30, Biogen Idec and Exelixis confirmed leadership changes that will result in Exelixis's long-time CEO George Scangos taking the helm of the Big Biotech July 15
Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
After spending $257 million and pushing into Phase III trials for a rare thyroid cancer, Bristol-Myers Squibb ends its deal. Exelixis CEO George Scangos says: "There is no smoking gun."